INTRODUCTION
Inequitable access to coronavirus disease 2019 (COVID-19) products, particularly vaccines, is a pressing problem. Dr Tedros, the Director-General of the World Health Organization (WHO), announced in late April 2021 that only 0.3% of the COVID-19 vaccines administered have reached the citizens living in developing countries. Little has changed since then. On 5 July 2021, Padma reported that, according to recent data, ‘only 1% of people in low-income countries have been given at least one dose’. This is not surprising when developed countries account for 6 billion of the total 8.6 billion dosages purchased so far …
Katarina Foss-Solbrekk, The IP waiver and COVID-19: reasons for unwavering support, Journal of Intellectual Property Law and Practice, volume 16, issue 12, December 2021, pages 1347-1359, https://doi.org/10.1093/jiplp/jpab150. Published: 11 December 2021.
First posted 2022-01-10 08:00:54
Leave a Reply